These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 20976880)

  • 1. [Susceptibility surveillance of clinical isolates to fluoroquinolone antimicrobial agents from 2003 to 2008: post-marketing study of prulifloxacin].
    Kawai S; Yoshida A; Okazaki M; Tsujihara Y; Inuzuka K; Takeuchi K; Yamashita N; Onodera M; Hiraishi T; Ida T; Maebashi K
    Jpn J Antibiot; 2010 Jun; 63(3):242-54. PubMed ID: 20976880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimicrobial activity of prulifloxacin in comparison with other fluoroquinolones against community-acquired urinary and respiratory pathogens isolated in Greece.
    Karageorgopoulos DE; Maraki S; Vatopoulos AC; Samonis G; Schito GC; Falagas ME
    Eur J Clin Microbiol Infect Dis; 2013 Nov; 32(11):1417-22. PubMed ID: 23686506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacologic characteristics of prulifloxacin.
    Matera MG
    Pulm Pharmacol Ther; 2006; 19 Suppl 1():20-9. PubMed ID: 16360331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical study of prulifloxacin on infectious enteritis. Japan Research Committee of Prulifloxacin, Research Group on Infectious Enteritis].
    Tomizawa I; Takizawa Y; Nitta Y; Tsunoda T; Fukuda H; Yamaguchi T; Masuda G; Negishi M; Ajisawa A; Murata M; Ohnishi K; Irimajiri S; Obana M; Sajima Y; Sagara H; Kato H; Hosoda S; Banba T; Sasaki M; Yoshikawa K; Nakagawa M; Ohkubo H; Kim Y; Akao M; Fukuyama M
    Kansenshogaku Zasshi; 1996 Jul; 70(7):727-45. PubMed ID: 8797308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Surveillance of in vitro susceptibilities to levofloxacin and various antibacterial agents for 11,762 clinical isolates obtained from 69 centers in 2013].
    Yamaguchi K; Tateda K; Ohno A; Ishii Y; Murakami H
    Jpn J Antibiot; 2016 Feb; 69(1):1-25. PubMed ID: 27290827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [In vitro activity of sitafloxacin against clinical isolates in 2009].
    Amano A; Matsuzaki K; Kishi N; Saika T; Hasegawa M; Ikeda F; Matsumoto T; Yamaguchi H; Kanda Y; Shiozawa T
    Jpn J Antibiot; 2010 Dec; 63(6):411-30. PubMed ID: 21425595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro antimicrobial activity of fluoroquinolones against clinical isolates obtained in 1989 and 1990.
    Chen YC; Chang SC; Hsu LY; Hsieh WC; Luh KT
    J Formos Med Assoc; 1993 Dec; 92(12):1040-8. PubMed ID: 7911351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [In vitro susceptibilities to levofloxacin and various antibacterial agents of 12,866 clinical isolates obtained from 72 centers in 2010].
    Yamaguchi K; Ohno A; Ishii Y; Tateda K; Iwata M;
    Jpn J Antibiot; 2012 Jun; 65(3):181-206. PubMed ID: 23173294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [In vitro activity of sitafloxacin against clinical isolates in 2012].
    Amano A; Matsuzaki K; Kishi N; Koyama H; Hasegawa M; Ikeda F; Matsumoto T; Yamaguchi H; Okutani Y
    Jpn J Antibiot; 2013 Dec; 66(6):311-30. PubMed ID: 24649797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
    Fritsche TR; Biedenbach DJ; Jones RN
    Antimicrob Agents Chemother; 2009 Mar; 53(3):1221-4. PubMed ID: 19114678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of Salmonella spp. with resistance to extended-spectrum cephalosporins and fluoroquinolones isolated in North America and Latin America: report from the SENTRY Antimicrobial Surveillance Program (1997-2004).
    Biedenbach DJ; Toleman M; Walsh TR; Jones RN
    Diagn Microbiol Infect Dis; 2006 Jan; 54(1):13-21. PubMed ID: 16290025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [In vitro antibacterial activity of prulifloxacin, a new oral quinolone, and comparative susceptibility rate at clinical breakpoint MIC].
    Inoue M; Kuga A; Kaieda S; Hosaka M; Kitasato H; Sato Y; Okamoto R; Eda T; Hoshino K; Seto I
    Jpn J Antibiot; 2000 Sep; 53(9):593-608. PubMed ID: 11214999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prulifloxacin.
    Keam SJ; Perry CM
    Drugs; 2004; 64(19):2221-34; discussion 2235-6. PubMed ID: 15456336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of fluoroquinolone-resistant beta-hemolytic Streptococcus spp. isolated in North America and Europe including the first report of fluoroquinolone-resistant Streptococcus dysgalactiae subspecies equisimilis: report from the SENTRY Antimicrobial Surveillance Program (1997-2004).
    Biedenbach DJ; Toleman MA; Walsh TR; Jones RN
    Diagn Microbiol Infect Dis; 2006 Jun; 55(2):119-27. PubMed ID: 16530373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of prulifloxacin against Escherichia coli isolated from urinary tract infections and the biological cost of prulifloxacin resistance.
    Gualco L; Schito AM; Schito GC; Marchese A
    Int J Antimicrob Agents; 2007 Jun; 29(6):679-87. PubMed ID: 17363225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1996). I. Susceptibility distribution].
    Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Shigeta S; Takahashi T; Shiraiwa Y; Ogiwara M; Yoshida H; Imafuku Y; Murai M; Watanabe K; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Igari J; Oguri T; Yamaguchi K; Matsumoto T; Kashitani F; Kaku M; Ooe H; Mochida C
    Jpn J Antibiot; 1998 Feb; 51(2):69-111. PubMed ID: 9575437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of the susceptibility trends in Japan to fluoroquinolones and other antimicrobial agents in a nationwide collection of clinical isolates: A longitudinal analysis from 1994 to 2016.
    Tateda K; Ohno A; Ishii Y; Murakami H; Yamaguchi K;
    J Infect Chemother; 2019 Aug; 25(8):594-604. PubMed ID: 30954447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of garenoxacin tested against a worldwide collection of ciprofloxacin-susceptible and ciprofloxacin-resistant Enterobacteriaceae strains (1999-2004).
    Sader HS; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2007 May; 58(1):27-32. PubMed ID: 17383140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (2001)].
    Shimada K; Oguri T; Igari J; Ikemoto H; Mori T; Kitamura N; Nakano K; Suzuki Y; Yokouchi H; Karasawa Y; Terai T; Yamamoto M; Nakata K; Nakatani T; Inoue H; Nakadate T; Inagawa H; Suwabe A; Obata R; Kudo K; Kobayashi N; Ohno I; Okada S; Hayashi K; Kinoshita T; Konosaki H; Arakawa M; Gejyo F; Kobayashi H; Goto H; Igarashi K; Kawai S; Okada M; Ito A; Sumitomo M; Aoki N; Matsushima T; Niki Y; Suga M; Hirakata Y; Aoki S; Matsuda J; Tosaka M; Nasu M; Nagai H; Kohno S; Tomono K; Miyazaki Y; Hiramatsu K; Nakano T
    Jpn J Antibiot; 2003 Oct; 56(5):365-95. PubMed ID: 14692377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changing antimicrobial susceptibility patterns among Streptococcus pneumoniae and Haemophilus influenzae from Brazil: Report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Castanheira M; Gales AC; Pignatari AC; Jones RN; Sader HS
    Microb Drug Resist; 2006; 12(2):91-8. PubMed ID: 16922623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.